Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
a study on Cutaneous T-Cell Lymphoma Lymphoma T Cell Lymphoma Mycosis Fungoides Chronic Lymphocytic Leukemia Leukemia
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- Thomas Kipps, MD, PhD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSD
- Thomas Kipps, MD, PhD
Thomas Kipps, MD, PhD, is Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, and Deputy Director of Research Operations at the UC San Diego Moores Cancer Center. He received his Ph.D. in Immunology and M.D. from Harvard University and had his residency and fellowship training in Internal Medicine, Hematology, and Genetics at Stanford University.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- miRagen Therapeutics, Inc.
- ID
- NCT02580552
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated